Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus or Rheumatoid Arthritis
NCT07276958Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, single-blind trial of LY4298445 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) at Week 52. Started Feb 2026; status: recruiting.
02
Drugs
LY4298445
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07276958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276958.